Abstract library

136 results for "predictors of malignancy".
#296 Tumor Size Correlates With Malignancy in Non-Functioning Pancreatic Endocrine Tumor
Introduction: Tumor size is a criterion of staging in non-functioning pancreatic endocrine tumors (NF-PET), as well as a predictor of outcome after curative resection.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Massimo Falconi
#1155 Evaluation of Features and Predictors for Long Term Hematologic Toxicity in Neuroendocrine Patients Treated with Peptide Receptor Radionuclide Therapy
Introduction: Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET) may offer partial or complete objective response in up to 30% of patients. To deliver treatment in a safe and effective manner, long term adverse events should be considered.
Conference: 12th Annual ENETS Conference (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Suzanne Richter
Keywords: PRRT
#1209 Pancreatic Neuroendocrine Incidentalomas: When is Surgery in the Patient’s Best Interests?
Introduction: Small PNETs, many of which are diagnosed incidentally, pose a management dilemma. Whilst resection offers curative outcomes, the risks of surgery have led many to adopt surveillance strategies. 2cm is often used as a threshold for malignancy, but reports suggest that this value may not be valid.
Conference: 12th Annual ENETS Conference (2015)
Category: Surgical treatment
Presenting Author: Logan Mills
Keywords: PNET
#669 Incidence of Second Malignancy in Patients with Neuroendocrine Tumors (NETs) of the Ileum and Colon (MGC)
Introduction: Increased incidence of second malignancy is observed in NETs (Kamp et al 2012).
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Professor Joy Ardill
#246 SDHB Loss Predicts Malignancy in Pheochromocytomas/Sympathethic Paragangliomas, but Not Through Hypoxia Signalling
Introduction: To date there is no reliable histopathological marker of malignancy for pheochromocytomas/sympathetic paragangliomas (PCC/PGL). It is well-known that PCC/PGL in the hereditary context of an SDHB germline mutation very often metastasize. The immunohistochemical loss of SDHB expression was recently shown to be a surrogate marker for the presence of an SDH germline mutation in PCC/PGL. SDHB loss is supposed to be tumorigenic via activation of hypoxia signals.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Anja M Schmitt
#1350 Understanding a Neuroendocrine Tumors’ Impact on Health Systems: A Population-Based Economic Analysis of Patterns of Costs
Introduction: Little is known on resource utilization and health care costs in NET care.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Hallet Julie
Authors: Hallet J, Law C, Cheung M, Fischer H, ...
Keywords: costs, care patterns
#353 Pattern and Clinical Predictors of Lymph Node Involvement in Neuroendocrine Neoplasms of the Pancreas
Introduction: Pancreatic neuroendocrine neoplasms (PNENs) are often indolent without pathological lymph node metastasis (pN1). Therefore, in patients with low risk of pN1, a lymphadenectomy could be avoided.
Conference:
Category: Basic
Presenting Author: Stefano Partelli
#635 Neuroendocrine Tumors of the Gastrointestinal Tract with Second Primary Malignancy
Introduction: Neuroendocrine tumors of the gastrointestinal tract (NETs of GIT) are rare neoplasms frequently associated with synchronous or metachronous second primary malignancy (SPM). This phenomenon can be a result of an increasing incidence of NETs in patients who are examined for another primary malignancy. However, other theories suppose genetic predispositions or growth impact of different neuroendocrine peptides produced by NET.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MUDr., PhD. Katarina Machalekova
Authors: Machalekova K, Kajo K, Kajo M, ...
#2141 Potential Role of SST5TMD4-Derived Peptides in the Malignancy of Neuroendocrine Tumors and Other Endocrine-Related Cancer Cells
Introduction: Extracellular fragments derived from membrane receptors can play relevant functional roles in certain tumoral pathologies and could provide novel diagnostic or therapeutic tools. We have identified a novel truncated somatostatin receptor type 5 variant, sst5TMD4, which is overexpressed and functionally active in different endocrine-related cancers, including neuroendocrine tumors (NETs). Interestingly, sst5TMD4 has 4 transmembrane domains and its C-terminal tail is consequently exposed towards the extracellular matrix, and could, therefore, be the substrate for proteolytic enzymes.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Sergio Pedraza-Arévalo
#2066 Pretherapeutic Predictors of Tumor Absorbed Dosimetry in Radionuclide Therapy for Metastatic Neuroendocrine Tumors
Introduction: Pretherapeutic 68Gallium-DOTA-(0-Tyr3)-octreotate Positron Emission Tomography (68Ga-DOTATATE PET) standardised uptake value (SUV) has shown conflicting results in the prediction of tumour lesion absorbed dosimetry (TLAD).
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Rahul Ladwa
Authors: Ladwa R, Pattison D, Smith J, Goodman S, ...